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Substantial advances have been made recently in the pathobiology of pituitary tumors. Similar to 
many other endocrine tumors, over the last few years we have recognized the role of germline and 
somatic mutations in a number of syndromic or non-syndromic conditions with pituitary tumor 
predisposition. These include the identification of novel germline variants in patients with familial or 
simplex pituitary tumors and establishment of novel somatic variants identified through next 
generation sequencing. Advanced techniques have allowed the exploration of epigenetic 
mechanisms mediated through DNA methylation, histone modifications and non-coding RNAs, such 
as microRNA, long noncoding RNAs and circular RNAs. These mechanisms can influence tumor 
formation, growth and invasion. While genetic and epigenetic mechanisms often disrupt similar 
pathways, such as cell cycle regulation, in pituitary tumors there is little overlap between genes 
altered by germline, somatic and epigenetic mechanisms. The interplay between these complex 
mechanisms driving tumorigenesis are best studied in the emerging multi-omics studies. Here, we 
summarize insights from the recent developments in the regulation of pituitary tumorigenesis. 
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List of abbreviations 
ACTH-PT Adrenocorticotropic hormone-secreting pituitary tumor 
circRNA circular RNA  
FIPA Familial isolated pituitary adenomas 
GH-PT Growth hormone-secreting pituitary tumor 
GT-PT Gonadotropin (FSH/LH)- secreting pituitary tumor 
Gαi Inhibitory Gα protein subunit 
HGVS Human Genome Variation Society 
lncRNA Long non-coding RNAs  
PitNET Pituitary neuroendocrine tumor 
PRL-PT Prolactin-secreting pituitary tumor 
PT Pituitary tumor 
SSA Somatostatin analogue 
TSH-PT Thyroid stimulating hormone-secreting pituitary tumor 
WES Whole exome sequencing  
WGS Whole genome sequencing 






















Pituitary tumors (PTs) are common intracranial neoplasms with an overall prevalence estimated at 
17% in a systematic review using post-mortem (14%) and radiologic studies (22%) (1). While the 
majority of these would represent incidentalomas and usually of little clinical significance, the 
prevalence of clinically-presenting adenomas is higher in epidemiological studies conducted over the 
last 10-15 years compared to older data, probably due to better diagnostic modalities, with 68-110 
PTs clinically-presenting cases identified per 100,000 inhabitants (2-8). Using incidence data from 
population-based state cancer registries in the United States, the age-adjusted annual incidence rate 
of PTs increases from 2.52 in 2004 to 3.13 in 2009 (per 100,000 subjects) (9). 
Tumors of the anterior pituitary usually do not metastasize, and hence have been referred to as 
“adenomas”. However, as a significant minority can show clinically aggressive behavior and similar 
characteristics to true metastasizing lesions (10), the term ‘pituitary neuroendocrine tumor’ or 
‘PitNET’ has been coined recently (11,12). Here we use the term pituitary tumor representing tumors 
arising from the potentially hormone-producing cells of the anterior pituitary. 
PTs are clinically categorized by their hormone-secreting characteristics, with over-secretion of GH, 
prolactin, ACTH, TSH and LH/FSH or clinically non-functioning tumors. Histological characterization 
has been based on immunohistochemical staining of pituitary hormones, with more recently 
transcription factors (PIT1 for GH, prolactin and TSH lineages, SF1 for gonadotroph lineages and TPIT 
for ACTH lineage) being added to the classification (13). Therefore, the final diagnosis relies on the 
combination of the clinical picture (excess hormone secreting or not) and histological assessment 
(hormone and transcription factor immunostaining (14)). Molecular characterization based on 
methylation patterns, gene expression and DNA mutations may add further granularity to the 



















Over the last decade, we have witnessed major advances in the biology of pituitary tumors, with the 
identification of several germline and somatic mutations and epigenetic mechanisms, such as DNA 
methylation, histone modifications and non-coding RNAs. In this review, genetic and epigenetic 
mechanisms contributing to pituitary tumorigenesis will be succinctly summarized with an emphasis 
on novel insights over the last ten years.  
 
1. GENETIC MECHANISMS OF TUMORIGENESIS 
 
1.1 Germline mutations driving tumorigenesis 
Pituitary tumors associated with germline mutations may present as part of a syndromic disease or 
in isolation (Figure 1, 2). The non-syndromic group consists of patients in whom no other organ than 
the pituitary is involved, and is known as familial isolated pituitary adenoma (FIPA) (16). We 
summarize here the key genetic aspects, while refer to other reviews on the detailed clinical 
characteristics of these diseases (17,18). 
 
1.1.1 Familial isolated pituitary adenoma (FIPA) 
The prevalence of FIPA among all PT patients was found to be 1.9-3.8% in pituitary referral centers 
(2,19). The first identified gene underlying FIPA is AIP (20), which accounts for 10-20% of FIPA 
kindreds (21,22). Duplication of GPR101 in X-linked acrogigantism (XLAG), although mostly identified 
as de novo mutation, has also been described in families (three kindreds described so far in the 
literature (23-26)). However, patients with a suggestive family history with no known genetic cause 
form the majority of patients in FIPA.  
1.1.1.1. AIP mutation-positive pituitary tumors 
The AIP gene maps to chromosome 11q13.2, incidentally close to the locus of the MEN1 gene, 



















expressed co-chaperone protein with multiple partners, but currently its role in pituitary 
tumorigenesis is incompletely understood. It behaves as a tumor suppressor with a unique primarily 
somatotroph/lactotroph specificity, although global lack of AIP is lethal in mouse, Drosophila and C. 
elegans studies (27-29). The cAMP/protein kinase A/phosphodiesterase pathway plays a key role in 
somatotroph physiology and acromegaly-related genetic syndromes (Figure 3). Not surprisingly, 
therefore, a link has been found between this pathway and AIP at several levels: at the inhibitory 
Gαi-2 protein (30,31), at cAMP (32), at phosphodiesterase 4A (33-35), at protein kinase A (36,37), 
downstream of somatostatin receptors and Zac1 (38,39) levels. AIP has also found interact and 
inhibit the endoplasmatic reticulum calcium channel ryanodine receptor in C. elegans (29), another 
pathway closely linked with hormone release, with somatic variants identified in calcium-related 
pathways from somatotropinomas (40,41). Given the particular role of RET in somatotroph cells (42), 
the link with RET (43) could be a link to the specific role of AIP in somatotrophs. Increased GH 
release has been found in AIP-disrupted cells, probably associated with the increased STAT3 
phosphorylation (39,44), while an altered microenvironment may also explain the aggressive 
phenotype of some of these tumors (45). However, the role of other AIP partners – nuclear 
receptors (AHR, ER, GR, PPRα, TRβ1), mitochondrial proteins, survivin (reviewed in (46)) or BCL6 (47) 
in the pituitary-specific effects is unclear.  
Pituitary tumors are significantly more frequent in global heterozygous Aip+/- mice compared to wild-
type mice (48). The majority of the tumors developed were GH-PTs, which were negative for AIP 
immunostaining. This predisposition to developing GH-PTs in the heterozygous state with loss of 
expression of AIP in the tumor is similar to the human clinical phenotype. Interestingly, full 
penetrance is achieved in global heterozygous Aip+/- mice by 15 months in contrast to the 23% 
penetrance observed in a large, thoroughly screened family (49). The discrepancy between the 
mouse and human phenotype is likely to be due to genetic variability in humans. Supporting this 
hypothesis is that fact that, although using the same mouse line, phenotypic variability has been 



















model with no pituitary tumors detected at 12 months of age (50), in contrast to Raitila et al. where 
pituitary tumor incidence was greater than 80% by 12 months. Homozygous somatotroph-specific 
knockout showed over 80% penetrance of GH-PTs by 10 months (51), with animals showing features 
similar to acromegaly (increased body size and elevated serum GH and insulin-like growth factor 1). 
High penetrance has also been observed in pituitary-specific Aip-knockout both in heterozygote and 
homozygote cases by 12-15 months (45,52). 
Patients with germline AIP mutations have a clinical phenotype that is distinct from sporadic tumors: 
they show earlier disease onset and are diagnosed at a younger age, are larger, and are 
predominantly sparsely-granulated GH-secreting tumors, locally invasive and develop apoplexy 
(21,22,33,53-55). These tumors are less likely to respond to first-generation somatostatin analogues 
(SSA) (33,53,56), while some cases have shown responses to second-generation SSA, pasireotide 
(57). 
Families with AIP mutations show an incomplete penetrance of around 15-30% (20,22,49,53). This 
probably explains why 50-70% of the identified AIP mutation positive kindreds do not have a known 
family history (simplex cases) (22,53), while de novo mutations (58) are exceedingly rare. Genetic 
screening can identify carrier family members, and clinical screening leads to a surprisingly high 
percentage of earlier recognition of clinically relevant disease (22).  
The prevalence of AIP mutations in patients with sporadic pituitary tumors varies significantly 
depending on age of disease onset, family history and tumor type (59). It is highest among patients 
with gigantism, 29%-41% (60,61), 12% in sporadic patients with age at diagnosis less than 30 years 
(62), and 3.6% of unselected population of a pituitary referral center (63). However, several studies 
found no pathogenic or likely pathogenic mutations in a cohort of 127 adult PT patients less than 40 
years at diagnosis (64), or in a group 50 of SSA-resistant adult patients with acromegaly (56). Current 
recommendations suggest screening for AIP mutations in patients with no syndromic features and 



















years or younger (16,65,66). 
 
1.1.1.2. X-linked acrogigantism (XLAG) 
XLAG is an extremely rare condition showing early-onset gigantism secondary to germline or somatic 
microduplication of the Xq26.3 chromosomal region containing the GPR101 gene (23).  
GPR101 is an orphan G-protein coupled receptor, with constitutive activity of the human protein. 
GPR101 is predicted to couple to the Gα stimulatory protein (67), which activates adenylyl cyclase 
and increases cAMP production. Indeed, culture of pituitary tissue of an XLAG patient showed 
increased GH and prolactin release (68), and heterologous in vitro overexpression of human GPR101 
leads to increased cAMP signaling in HEK293 cells (67) and GH3 cells (23). GPR101 is expressed in the 
normal human hypothalamus and in the embryonic and pubertal pituitary, but less in prepubertal 
and adult pituitary, suggesting a role in development and at the peak of growth (69). GPR101 is 
overexpressed in XLAG pituitary tumors, while expression in sporadic GH-PTs is low (23). The 
hypothalamic expression could explain the increased GHRH levels measured in some of the patients, 
and points to the role of hypothalamic dysregulation in this disease (68).  
Recently, a lipid mediator n-3 docosapentaenoic-derived resolvin D5 (7S,17S-dihydroxy-
8E,10Z,13Z,15E,19Z-docosapentaenoic acid, RvD5n-3 DPA) has been shown to activate GPR101, 
representing a potential endogenous ligand to  this previously orphan receptor (70). This bioactive 
lipid mediator enzymatically derived from essential fatty acid n-3 docosapentaenoic acid is a 
member of the specialized pro-resolving mediators. It plays a role in the regulation of leukocytes and 
macrophages, intestinal barrier protection and in joint inflammation. It is currently unknown 
whether this ligand has a role in the physiological regulation of the GH axis and how it behaves in 
patients with XLAG. A previously suggested putative ligand for GPR101 is GnRH-(1-5), a short 
fragment of GnRH. GnRH-(1-5) has been suggested to activate GPR101 to increase epidermal growth 



















cellular migration and leading to an increase in cellular invasion (71). Similar pro-proliferation and 
pro-invasive effects may underlie pituitary tumorigenesis in XLAG. 
 
The majority of the reported XLAG cases are sporadic (26 patients) due to de novo mutations, while 
three kindreds have been reported in the literature to date (23-26,61,68,72-74). The majority of the 
patients are females (24/33, 73%), with all female cases showing de novo germline duplication, 
making transmission to future generations possible (75). In males, XLAG is secondary to somatic 
mosaicism in simplex cases described so far (72,76), or to germline duplications inherited from an 
affected mother (full penetrance was seen in all three kindreds) (23-26). Two of 3 familial female 
patients described so far are mothers of affected sons and have de novo mutations; all four familial 
male patients are affected sons who have inherited the duplication from their mothers (23-26). It is 
unclear why de novo germline mutations have not so far been described in males.  
Patients with XLAG have a distinct clinical phenotype with the onset of symptoms and diagnosis in 
early childhood (23,61). Clinical presentation in most cases is due to accelerated growth velocity in 
infancy or early childhood (<5 years of age; most commonly during the first 2 years of life) (61) with 
acromegaly-type features such as acral enlargement and coarse facial features, signs which are often 
not seen in patients with other types of childhood-onset acromegaly (26). The majority (~80%) of the 
patients present with a GH and prolactin-secreting macroadenoma (23,61). Some of the patients 
have a normal-sized pituitary gland or diffusely enlarged histologically-proven pituitary hyperplasia 
(61,72,77), despite very high levels of GH and IGF-1, with or without prolactin elevation. A prenatally 
diagnosed familial XLAG case showed a pituitary tumor on MRI already at 3 weeks of age, associated 
with high prolactin and growth hormone (24,25). Given the full penetrance observed so far in 
familial XLAG, preimplantation diagnosis or prenatal screening is worth considering in affected 
mothers, and theoretically in female fetuses of affected males (although male-to-female 



















a mixed sparsely and densely granulated pattern (25,26,61,73). No other PT type has been 
associated with GPR101 duplications (78). Missense variants of GPR101 do not seem to be 


















1.1.1.3 Novel germline variants  
Comprehensive reviews of clinical and genetic aspects of germline syndromes are available elsewhere: here we briefly summarize here the more recent 
developments (Figure 1).  
The vast majority of FIPA does not have an established genetic basis: approximately 85% of the FIPA cohort were negative for AIP mutations in one study 
(21). Consequently, there has been significant interest in identifying other germline variants, which may predispose to familial tumors (Table 1), but none of 
the published data convincingly supports the established presence of a further gene causing FIPA.  
Four heterozygous germline missense variants were identified in CABLES1 in four sporadic patients from a cohort of 182 patients with ACTH-PTs with 
functional evidence of loss of function for some of them (Table 1). No familial cases have been reported to date (81).   
While loss of the Prlr leads to large pituitary tumors in mice, homozygous loss-of-function PRLR mutation in a human patient with hyperprolactinemia and 
agalactia had no pituitary tumor (82). On the contrary, a gain-of-function variant was identified in 9 out of 46 patients with PRL-PTs, representing a possible 
novel mechanism for prolactinoma tumorigenesis. In addition, 3 other rare and 2 low-frequency variants found in this cohort may represent benign changes 
(83). Further data are needed to confirm these findings. Furthermore, no loss or gain-of-function mutations could be identified in a cohort of young 88 patients 
with PRL-PTs (84) or in a cohort of 16 PRL-PT (15). 
There are some further reports of germline variants in patients with pituitary tumors but without functional elucidation to define pathogenicity or mechanisms. 
Investigation into a family with isolated PRL-PTs (3 affected siblings) with whole exome sequencing showed novel, germline, potentially pathogenic variants in 
RXRG and TH  (85), the latter of which may be relevant  as it encodes tyrosine hydroxylase which mediates the rate-limiting step in the formation of 
dopamine which, in turn, negatively regulates prolactin secretion in the pituitary. Further cases or functional studies will strengthen this report. 
Using whole exome sequencing, a study of 12 FIPA families identified four families with germline variants in CDH23, which were predicted to be pathogenic 
using in silico analysis. Tumors of these patients showed a reduced frequency of cavernous sinus invasion, compared to the rest of the familial patients. The 



















is a large gene and therefore is, in general, more likely to harbor sequence variants. Homozygous mutations in CDH23 result in Usher syndrome, 
characterized by congenital sensorineural hearing loss, vestibular dysfunction and early-onset retinitis pigmentosa (86). Pituitary tumors have not been 
described in association with any of these problems (87). This study also describes 2 (out of 125) sporadic pituitary tumor patients with homozygous CDH23 
variants (88), but it is not specified whether these individuals showed clinical manifestations of Usher syndrome. 
Interestingly, a recently-described syndrome, X-linked IGSF1 deficiency characterized by central hypothyroidism, macro-orchidism (89) and prolactin 
deficiency (90), can be associated with acromegaloid facial features, increased head circumference and increased total GH secretion and IGF-1 levels (91). 
Given that patients show hyperplasia rather than adenomas, this may be secondary to a failure of regulatory and feedback mechanisms. A germline variant 
in IGSF1 was identified in three family members with gigantism (due to somatomammotroph hyperplasia, rather than adenoma) (92). No effect of the 
variant on protein expression, maturation, stability, or membrane trafficking was observed. The authors speculate that, given the prediction that the 
modified residue changes the surface charge in the 6th immunoglobulin loop, this may alter IGSF1’s interaction with an extracellular partner, although this 
variant is reasonably common in the general population (minor allele frequency is 0.009, Table 2). 
 
1.1.2 Syndromes associated with pituitary tumors 
 
In addition to the previously well-described syndromes with multiple tumor types where pituitary tumors represent one of the possible manifestations, 
several novel syndromes have been described over the last few years (Figure 2). The MEN1 syndrome is due to germline loss-of-function mutations of the 



















An MEN1-like clinical picture can be seen in MEN4 syndrome due to mutation in cyclin dependent kinase inhibitors, primarily p27 (CDKN1B) and rarely in 
p21 (CDKN1A), p15 (CDKN2B) and p18 (CDKN2C) (96,97). 
In Carney complex, in addition to loss-of-function mutations in the regulatory protein kinase A subunit PRKAR1A, gain-of-function has been described in the 
catalytic protein kinase A subunit PRKACB (98). The disease-causing gene associated to the 2p16 locus in Carney complex cases is unknown.  
While pituitary tumors and pheochromocytoma are rarely seen in MEN1 syndrome, the constellation of paraganglioma, pheochromocytoma and pituitary 
tumor (‘3P’ association) is now increasingly recognized in patients with SDHx mutations (99,100) with a characteristic histological phenotype (99) and 
pituitary adenomas developing in a Sdhb-knockout mouse model (101). MAX mutations have been identified in 5 patients with pituitary tumor and 
pheochromocytoma (102-104). While loss-of-heterozygosity has not been shown yet, further data are needed to confirm a causal relationship between 
MAX mutations and pituitary tumors.  
Corticotroph tumors have been recently identified in three tumor syndromes.  DICER1 syndrome (loss-of-of-function DICER1 mutations) has shown 
infantile-onset large pituitary blastoma in a few patients (105). Germline mutations in the mismatch repair pathway (MLH1, PMS2, MSH2, MSH6) lead to 
Lynch syndrome, an autosomal dominant inherited cancer syndrome associated with colorectal, endometrial, ovarian and other carcinomas. Germline 
mutations in MLH1 (106) and MSH2 (107) have been identified in patients with aggressively growing ACTH-secreting tumors. While somatic variants were 
found in a single non-functioning tumor in 4 mismatch-related genes (108), microsatellite instability was not found in 107 sporadic pituitary tumor samples 



















dysmorphic features, developmental delay and a corticotroph tumor (110), with a second similar case now under workup (Stratakis, NIH, personal 
communication).  
Rarely, optic pathway gliomas cause high GH levels in neurofibromatosis type 1 (NF1), while true pituitary adenomas are extremely rare. Pituitary tumors 
have been reported in patients with tuberous sclerosis (111-114). It is currently unclear if these are indeed related to the TSC1 or TSC2 mutations or are 
coincidental findings.  
 
1.2 Somatic mutations driving tumorigenesis 
The most common recurrent somatic mutations occur in GNAS in somatotroph tumors, and in USP8 in corticotroph tumors. Other somatic changes 
suggested to be associated with pituitary tumors include: PIK3CA amplification (115,116), IDH1 mutations (117,118), TP53 in pituitary carcinomas (119) and 
ACTH-PTs (120),  and HMGA2 amplification in PRL-PTs (121-123). HRAS mutations have been seen in pituitary carcinoma (124), while the report of complex 
1 mitochondrial mutations in oncocytomas (125) await confirmation. A somatic frameshift mutation in the glucocorticoid receptor gene (NR3C1) resulting in 
premature termination of the coding sequence has been described in a patient with Nelson’s syndrome, which may contribute to tumor development by 
reducing glucocorticoid feedback on tumor cells (126). No coding region NR3C1 mutation was found in 18 ACTH-PTs using Sanger sequencing (127), or in 18 
USP8 mutation-negative PTs using exome sequencing (120).  A single patient with a de novo missense germline NR3C1 mutation associated with an ACTH-









































GNAS encodes the stimulatory α subunit of G-proteins and shows the most frequent somatic mutations in GH-PTs, more recently confirmed through whole 
genome (WGS) (40) and whole exome sequencing (WES) (15,108,129,130). Mutations affect codon 201 or 227, disrupting the GTPase activity of the protein 
(131) and leading to prolonged adenylyl cyclase activity and increased cAMP levels, driving tumorigenesis (Figure 3). GNAS-mutated tumors are smaller 
(132-136), less likely to be locally invasive (136) and more likely to respond to SSAs (136,137), although a Brazilian cohort showed no differences in tumor 
extension or response to SSAs between mutated and non-mutated tumors (138). Dopamine receptor 2 expression is increased in GNAS-mutated tumors, 
potentially allowing for GNAS mutation status in predicting response to dopamine agonists in GH-PTs (15). Recently, DNA methylation-activated inhibitory 
Gα (Gαi) -signaling was found in GNAS-mutation-positive GH-PTs (139). Patients with somatic mosaicism for codon 201 GNAS develop McCune-Albright 
syndrome, characterized by somato- or somatomammotroph hyperplasia or tumor, polyostotic fibrous dysplasia, cafe-au-lait spots, and precocious puberty 
(140). 
 
1.2.2 USP8 and USP48 
Gain-of-function mutations in the deubiquitinase enzymes USP8 and USP48 are associated with ACTH-PTs (108,120,129,141-148). USP8 mutations disrupt 
the interaction between USP8 and 14-3-3 protein, thereby allowing USP8 cleavage and increased enzymatic activity (141-143); this protects EGFR from 
lysosomal degradation, which leads to increased expression of EGFR (141-143) (Figure 4) and pro-opiomelanocortin (POMC) (141,146). Inhibition of USP8 
leads to increased degradation of EGFR with suppresses corticotroph cell growth and ACTH secretion in vitro (149). Lapatinib, an EGFR inhibitor, decreases 



















with a higher prevalence in females (151). USP8-mutated tumors are associated with an earlier onset (143,152), smaller size (141) and increased ACTH 
production (141,152). In patients who showed biochemical remission after surgery, the incidence of recurrence in a 10-year follow-up was higher in 
patients with USP8 mutant tumors (152). In pediatric patients with Cushing’s disease, all recurrences after initial remission (in five patients) occurred in 
tumors with USP8 mutations (153). When remission status was investigated, the remission rates were higher in patients with USP8-mutated-alleles, 
although no recurrence was detected for at least 6 months after surgery (151). These data suggest that patients with USP8-mutated-tumors may be more 
likely to go into initial remission post-surgery but may also more likely to show recurrence later in the clinical course. USP8-mutation-negative tumors are 
more likely to show sphenoid invasion with an increased epithelial-mesenchymal-transition signature (15). Recently, SSTR5 expression has been shown to 
be higher in USP8-mutated tumors (15,146), potentially allowing the mutation status to be used as a predictor of response to pasireotide (a second 
generation SSA with greater affinity for SSTR5 (154)). In vitro studies found increased expression of pCREB and protein kinase A Cα on immunoblotting in 
AtT20 cells transfected with mutant USP8 (147). 
Activating USP48 mutations were found in 10-20% of ACTH-PTs (28,120). USP48 variants are associated with smaller tumors and better response to 
corticotropin releasing hormone (CRH) stimulation (120). Interestingly, both USP8 and USP48 have targets in the hedgehog signaling pathway: Smoothened 
for USP8 (155) and GLI1 for USP48 (120), suggesting that upregulation of this pathway may play a role in corticotroph mutagenesis (Figure 4).  
 



















Analysis of whole exome and whole genome sequencing data from pituitary tumors has revealed a low number of somatic mutations per tumor across all 
subtypes (108,129,130). This is consistent with their generally low proliferation rate. Only a handful of genes show recurrent mutations (108,156). Such 




















Table 3. Identifying somatic variants in circulating free DNA has been attempted recently (157), and 2 
may develop into a useful method to follow patients with pituitary tumors. 3 
Novel sequencing approaches have provided an opportunity to develop interesting insights into 
pituitary tumorigenesis: 
1. Novel candidate genes may point towards dysregulated pathways in tumorigenesis: 
The first genome-wide association study of sporadic pituitary tumors identified new 
candidates (158): CDK8 (cell cycle regulation) and NEBL and PCDH15 (cell-cell adhesion). 
CDK8 is an oncogene in colorectal (159) and gastric carcinoma (160) with differentially 
expressed genes from animal PRL-PT models showing enrichment for CDK8 targets (161). 
Targeted mutation profiling of canonical cancer-associated genes has identified recurrently 
mutated genes, with three main pathways implicated in tumorigenesis in one study: cell cycle 
regulation and growth, chromatin modification and transcriptional regulation and DNA damage 
response (130). 
2. Subtype-specific mechanisms can be unveiled through WES and WGS studies 
focusing on tumor subgroups (Table 4): WES and WGS studies on GH-PTs have identified 
dysregulation of multiple signaling pathways as potential tumorigenic mechanisms, although 
they need to be characterized further using functional studies. Mutations in different genes 
can affect the same pathways and mediate tumorigenesis. For example, based several genes 
involved in cAMP signaling were found to have somatic variants in 14 of 36 somatotroph 
tumors, including G-protein-coupled receptors CCR10 and OR51B4, which were suggested to 





















3. Pathways mediating aggressive behaviors such as local invasion (irrespective of subgroups) 
can be identified for further functional characterization: WES comparing invasive and non-
invasive NFPTs and PRL-secreting tumors identified fifteen variants, which were mainly 
associated with processes involved in the regulation of invasion such as angiogenesis and 
cytoskeleton organization (162). ACTH-PTs with disrupted genomes and chromosomal 
instability are more likely to show cavernous sinus invasion (163). 
4. Whole exome/genome sequencing studies can be used to identify copy number alterations 
and degree of chromosomal instability, which can provide further insights into subtype-
specific tumorigenesis. Two distinct subgroups of pituitary tumors with low and high fractions 
of genomic disruption have been identified. The percentage of genome disruption used to 
define these two subgroups varies across studies (WES: (15,108,129,156,163), array-CGH 
(164)). Tumors with high genome disruption are enriched for hormone-secreting tumors, 
suggesting differing mechanisms of tumorigenesis between functioning and non-functioning 
tumors (15,156). Chromosomal instability is not related to aggressiveness (15). GH-PTs show 
greater genomic disruption than ACTH-PTs as well as inactive tumors with no clinical 
evidence of hormone secretion (108). Subgroups of GNAS-mutation negative GH-secreting 
tumors show high levels of genomic instability (139) with 20q amplification (GNAS locus) 
(15,130,164), which may be an alternative mechanism of increased signaling through GNAS 
driving somatotroph tumorigenesis. GH-PTs with recurrent aneuploidy showed high 
expression of pituitary tumor transforming gene 1 (PTTG1), which is a regulator of sister 
chromatid segregation, this may subsequently drive chromosomal instability (139,165,166). 
5. Next generation sequencing approaches can also be used in sequencing extrachromosomal 
DNA and identifying their role in tumorigenesis: tumors with the highest number of 
mitochondrial variants show the highest Ki-67 indices, irrespective of tumor subtype (167), 





















2. EPIGENETIC MECHANISMS OF TUMORIGENESIS 
 
While germline and somatic genetic alterations have provided interesting insights into pituitary 
tumorigenesis, still the majority of pituitary tumors are sporadic with no known somatic driver 
mutations. Epigenetic changes are heritable phenotypic changes, which do not alter the DNA 
sequence. These can regulate transcription and/or translation. Epigenetic mechanisms may occur at 
the chromatin level, such as DNA methylation and histone modification, or at the RNA level, mainly 
mediated by non-coding RNAs, such as microRNAs, long non-coding RNAs (lncRNA), circular RNA 
(circRNA) and others. Such mechanisms affect gene expression and, consequently, tumorigenesis, 
and have assumed great significance, especially given the paucity of somatic mutations. 
 
2.1 DNA methylation 
Recently, it has been shown that PIT-1 lineage tumors (GH-, PRL- and TSH-PTs) show global 
hypomethylation and cluster as a group with hypomethylation, chromosome alterations and 
transposable element overexpression (15), suggesting that DNA hypomethylation may induce 
chromosomal instability through upregulation of transposable elements. GNAS-mutation positive 
GH-PTs also showed hypomethylation but with limited chromosomal alterations (15); GNAS-
mutation positive tumors are associated with low levels of copy number alterations, as mentioned 
above. 
Promoter methylation can prevent access to transcriptional machinery, leading to decreased 
expression. A systematic review of genes implicated in epigenetic dysfunction in pituitary tumors 
identified 16 tumor suppressor genes that underwent silencing secondary to methylation, of which 




















i) Methylation of CpG islands in CDKN2A is seen in up to 90% of sporadic pituitary tumors 
(168,169,171-173) with loss of expression of p16 on immunohistochemistry (171,172),  
ii) Methylation of CpG islands in the RB1 promoter in sporadic tumors (169,173) is 
significantly associated with loss of expression on immunohistochemistry (174), 
iii) Transgenic mice with a disrupted Rb1 allele develop pituitary tumors (175). 
The systematic review also identified aberrant methylation in more than 50% of tumors in GADD45γ, 
CASP-8, PTAG and FGFR2 (168). GADD45γ, CASP8 and PTAG are involved in apoptosis modulation, 
while FGFR2 is a growth factor receptor. Growth factors and growth factors receptors can also be 
over-expressed in pituitary tumors (176,177).  
The epigenome may be modified by the de novo methyltransferases DNMT3A and DNMT3B. 
DNMT3A and DNMT3B is overexpressed in pituitary tumors (178,179) and frequently detected in 
invasive tumors (178). Reducing the expression of DNMT3B was associated with increased levels of 
hypo-phosphorylated Rb, p21 and p27 proteins and reduced proliferation (179), suggesting that 
increased expression DNMT3B may mediate proliferation through promoter hypermethylation and 
silencing of tumor suppressor genes. 
Gene imprinting is a process in which transcription of one allele is repressed through methylation, 
depending on the parent of origin. Relaxation of imprinting through loss of methylation can lead to 
increased transcription, such as in GNAS-mediated tumorigenesis (180). Imprinted genes such as 
MEG3 (discussed later) have only one transcriptionally-active copy, rendering them especially 
susceptible to inactivation through mutation or increased promoter methylation. 
DNA methylation is associated with clinical characteristics, such as: 
i) Tumor subtype: Microarray profiles differentiate between functioning tumors (including 
hormone subtypes) and NFPTs (108,181-184) with GH-PTs divided into sparsely and two 
densely granulated groups (182).  
ii) Local invasion: While one study has shown distinct microarray profiles between invasive 



















differences, both when only NFPTs were used (186) or with a diverse group of functioning 
and non-functioning tumors (183). Interestingly, differentially methylated genes were 
enriched for cell adhesion pathways (185). Decreased LAMA2 (187) and WIF1 (188) 
expression (RT-qPCR and immunoblotting) with increased promoter methylation is seen 
in invasive NFPTs (187). LAMA2 over-expression in a xenograft model significantly 
suppressed tumor growth (187). Greater promoter methylation of ESR1 and RASSF1 is 
seen in non-invasive compared to invasive tumors (184).  
iii) Tumor size: CDKN2A methylation and reduced expression of p16 are significantly 
related to larger tumor size (171,172). Macroadenomas show a greater frequency of 
promoter methylation of MSH6 and CADM1 than microadenomas (184). 
iv) Disease progression: TERT encodes a component of telomerase, which lengthens the 
telomere, mediates cell immortalization and is a well-recognized oncogene. Aberrant 
TERT promoter methylation is associated with TERT upregulation in malignancies (189-
191) and shorter progression-free survival and tumor recurrence (192) in pituitary tumors. 
v) Implications for therapy: MGMT promoter methylation and consequent low expression 
are noted in a subset of pituitary tumors (193,194). Temozolomide is currently used in the 
management of pituitary carcinomas and aggressive pituitary tumors (defined clinically as 
tumors that recur despite various treatment modalities such as surgery, radiotherapy and 
pharmacological therapy (195-197)). Immunohistochemistry to assess MGMT expression 
has been recommended prior to commencing temozolomide as high expression is 
associated with a lack of response, although the methodologies are not standardized and 
most clinicians would not use the result to discard temozolomide therapy (196,197). Loss 
of MSH2 and MSH6 has also been linked to developing rapid resistance to temozolomide 
(198). Patients with somatotropinomas and GSTP1 promoter methylation are more 





















2.2 Histone modification 
Acetylation, methylation and citrullination of histone tails are associated with active and inactive 
regions of the genome respectively. These epigenetic marks can be modified by chromatin 
regulators such as histone acetyltransferases, histone deacetylases, histone methyltransferases and 
citrullination enzymes.  
Several studies suggest that changes in histone acetylation play a crucial role in pituitary 
tumorigenesis: 
i) Tumor-specific ikaros isoform Ik6 promotes pituitary cell survival through enhanced anti-
apoptotic activity by up-regulation of Bcl-XL through promoter histone acetylation (200). 
ii) Expression of bone morphogenetic protein 4, which is a growth factor known to drive 
pituitary tumorigenesis (176), is controlled through histone acetylation and methylation 
(201). 
iii) Tumor subtype-specific changes: sirtuins are conserved histone deacetylases, which 
show differences in expression profiles in pituitary tumors based on size and hormone-
secreting subtype (202). Histone deacetylase-2 deficiency is seen in glucocorticoid-
resistant ACTH-PTs (203), with histone deacetylase-11 mediating decreased p53 
expression in corticotroph AtT-20 cells (204). Inhibition of histone deacetylase activity 
reduces survival and ACTH secretion in corticotroph cells (205). 
iv) Aggressive behavior: Histone acetyltransferases p300 upregulates human pituitary tumor 
transforming gene (hPTTG) (206). PTTG is a growth factor with a well-established role in 
carcinogenesis and invasion, partly regulated through the c-myc pathway (207). A meta-
analysis has confirmed increased PTTG expression in invasive pituitary tumors (208) (this 
has also been replicated in NFPTs (209)). Pituitary tumors show a global increase in 
H3K9 acetylation compared to normal pituitary, with increased acetylation seen in tumors 
with increased Ki-67 index (210). 
Histone methylation and citrullination (conversion of arginine to citrulline catalyzed by 
peptidylarginine deiminase enzymes) may also mediate tumorigenesis. Enhanced H3K27 methylation 



















thought to be a histone methyltransferase), which also correlates with longer progression-free 
survival (211). Non-invasive tumors also show significantly increased RIZ1 expression compared to 
invasive tumors (211). Citrullination of histone H3 in GH3 cells represses the expression of specific 
tumor suppressor microRNAs, which leads to increased expression of known drivers such as N-MYC, 
and IGF-1 and increased proliferation (212).  
 
2.3 MicroRNAs 
These are short non-coding RNAs that mediate post-transcriptional regulation of gene expression 
through RNA interference and mRNA destabilization. The role of microRNAs in pituitary 
tumorigenesis has been extensively reviewed elsewhere (213-215). The recent advances (mainly 




















2.4 Other non-coding RNAs  
These include long non-coding RNA (lncRNA) (200nt to ~100 kilobases long with no open reading 
frames (216)) and circular RNA (generated from exons of protein-coding genes and lacking a 5' cap 
or 3' poly (A) tail (217)). LncRNA and circRNAs have various functions, such as regulation of gene 
transcription and depletion of microRNA (‘microRNA sponge’). Their up- or downregulation can 
result in tumorigenesis (217). Many lncRNAs are imprinted, allowing for dysregulation of imprinting 
resulting in abnormal function (216) (see above).  
H19 expression is downregulated in pituitary tumors compared to normal pituitary (218) and H19 
suppresses proliferation in vitro and in vivo (219) by inhibiting mTORC1 (218). CCAT2 is significantly 
upregulated in pituitary tumors with elevated expression correlating with poor prognosis (220). 
CCAT2 enhances proliferation in HP75 cells by suppressing PTTG1 degradation (220). IFNG-AS1 
expression is greater in pituitary tumors with increased proliferation noted in HP75 cells on over-
expression, probably mediated through ESRP2 (221). AFAP1-AS1 expression is also increased in 
pituitary tumors (222) and promotes proliferation by acting as a competing endogenous RNA of miR-
103a-3p leading to activation of the PI3K/AKT pathway (223). 
LncRNAs may drive subtype differentiation: 
a) Genome-wide analysis of lncRNAs identified 839 differentially-expressed lncRNAs in GT-PTs 
compared to normal pituitary (224). Similar analysis in NFPTs identified 113 lncRNAs (225). 
b) RPSAP52 expression is highly upregulated in GT-PTs and PRL-PTs, where it increases 
HMGA2 levels, compared with normal pituitary tissues (226). This relationship is not seen in 
GH-PTs. 
c) LncRNA clarin 1 antisense RNA 1 (CLRN1-AS1) is downregulated in PRL-PTs therefore 
relieving inhibition from the Wnt/β-catenin pathway (227). 
d) Overexpression of a subgroup of long non-coding RNAs, termed “highly up-regulated in liver 
cancer” (HULC), promoted GH3 cell viability, migration, invasion and PRL and GH secretion 



















LncRNAs may also drive tumor invasion: 
a) MEG3: This is imprinted lncRNA, which is downregulated in NFPTs (229,230). Loss of 
expression is not seen in other tumor subtypes (231,232). Promoter hypermethylation 
mediates loss of expression (233). Ectopic expression inhibits growth in human cancer cell 
lines (229). MEG3 causes cell cycle arrest at the G1 phase with p53-dependent (234) and 
p53-independent (235) mechanisms. MEG3 expression is significantly reduced in invasive 
compared to non-invasive NFPTs (236). 
b) HOTAIR: Expression is significantly higher in NFPTs compared to normal pituitary and in 
invasive compared to non-invasive NFPTs (236). HOTAIR interacts with the Polycomb 
Repressive Complex 2 (PRC2) (237,238) and promotes invasion in pancreatic (239) and non-
small cell lung cancer (240). 
c) Lnc-SNHG1: Overexpression is seen in invasive pituitary tumors. Lnc-SNHG1 interacts with 
and decreases the activity of miR-302/372/373/520 in vitro, activating the TGFBR2/SMAD3 
and RAB11A/Wnt/β-Catenin (241). 
d) C5orf66-AS1: Its expression is decreased in invasive null cell adenomas compared to non-
invasive tumors (242) 
e) XIST:  XIST and bFGF exhibited high expression while miR-424-5p showed low expression in 
invasive compared to non-invasive pituitary tumor tissue. XIST was found to up-regulate 
bFGF expression by competitively binding to miR-424-5p (243): bFGF (basic fibroblast growth 
factor) acts as a growth factor and can also promote angiogenesis. 
Interestingly, multiple studies have shown a role for circRNAs in tumor progression in NFPTs. As 
discussed previously, miR-145-5p induces apoptosis in NFPTs; circOMA1 can promote tumor 
progression by sponging this microRNA (244). Differential circRNA expression profiles of invasive and 
non-invasive NFPTs have been shown (245,246), with gene enrichment for cell adhesion and 
PI3K/AKT pathways (245). Ten circRNAs are upregulated in recurrent compared to primary tumors 
(245). In fact, a signature of two circRNAs (hsa_circ_0000066 and hsa_circ_0069707) is suggested to 




















2.5 Global gene expression profiles 
Novel sequencing and array-based approaches have allowed for:  
a) Identification of distinct profiles in subtypes: Using RNA sequencing, six distinct transcriptomic 
profiles have been identified which match the WHO 2017 tumor classification (15) with the 
following discrepancies: i) Null cell subtype matches GT-PTs; ii) Silent and secreting ACTH-
PTs show distinct profiles: iii) Mixed GH-PRL tumors cluster with GH-PTs, rather than PRL-
PTs; and iv) Sparsely granulated GH-PTs cluster with thyrotroph and plurihormonal PIT1-
positive tumors rather than GH-PTs.  
Distinct tumor type-specific profiles were shown in earlier studies as well: GT-PTs (224,248-
250), ACTH-PTs (108,251-253), GH-PTs (108,254), PRL-PTs (255,256) and NFPTs 
(108,257,258). Insights from such studies include a confirmation of the importance of 
deregulation of the cell cycle in pituitary tumorigenesis across subtypes 
(15,249,250,254,257,259), deregulation of the mTOR signaling pathway in GT-PTs (224) and 
alterations in the Notch pathways in PRL-PTs (255) and NFPTs (258). A subtype of NFPTs 
may actively suppress the immune system, raising the possibility of immunotherapy in 
treatment (260). Integration of microarray datasets has also been used to identify immune-
related genes and further explore this possibility (261). Recently, evaluation of splicing 
machinery components in GH-PTs, ACTH-PTs and PRL-PTs showed severe dysregulation in 
all subtypes compared to normal (262).  
b) In a subgroup of tumors from patients with acromegaly, ectopic GIPR overexpression was 
associated with a paradoxical increase in GH after an oral glucose tolerance test (263,264). 
These GIPR-expressing somatotropinomas are negative for GNAS mutations (263,265). An 
overall hyper-methylator phenotype was identified in GIPR-expressing samples (compared 
with GNAS-mutated tumors), which also showed hypermethylation in the GIPR gene body, 
potentially driving ectopic expression (263). This represents a novel tumorigenic mechanism, 
similar to the well-described ectopic receptor induced adrenal tumors. 
c) A study on invasive pituitary tumors identified that the TNFα network ‒ including genes coding 
for proteins (TNFα, CCL3, CXCL12, and CCL2), microRNAs (miR-181c-5p and miR-454-3p) 



















adenomas compared non-bone-invasive counterparts, suggesting that targeting the TNFα 
pathway may be beneficial for these invasive tumors (266). 
 
2.6 Proteomics  
Novel techniques such as nanoscale liquid chromatography coupled to tandem mass spectrometry 
(nano LC-MS/MS) have been used recently (267) in determining proteomic profiles. Integration of 
such techniques with transcriptomics has allowed for identification of invasion-related biomarkers 
(268) and pathways (269) in NFPTs. This technique has even allowed for the identification of novel 
sites of phosphorylation in GH-PTs (267) with enrichment of differentially-expressed phosphorylated 
proteins for glycolysis and AMPK signaling. High-performance liquid chromatography coupled to 
mass spectrometry has been used to identify differentially-expressed molecules in fibroblasts 
isolated from bone-destructive NFPTs (270) (with significant upregulation of osteopontin, which can 
stimulate cell migration and invasion (271)). The first study to investigate protein ubiquitination 
profiling in pituitary tumors compared to normal pituitary showed enrichment for the PI3K/AKT 
signaling pathway in NFPTs (272). 
High-resolution Fourier transform mass spectrometry is another promising novel technique which 
has identified 105 novel proteins in the normal anterior pituitary compared with previous high-
throughput proteomic-based studies (273). Using this approach may also identify new candidate 
proteins and/or pathways driving pituitary tumorigenesis. Previously used techniques in proteome 
profiling of pituitary tumors include two-dimensional gel electrophoresis-based comparative 





















OTHER FACTORS INFLUENCING PITUITARY TUMORIGENESIS  
In this review we have concentrated on the novel genetic changes in pituitary adenomas. We refer 
to data on other important aspects of pituitary tumorigenesis, such as the role of senescence 
(277,278), cytokines (45,279) or tumor-associated fibroblasts (280,281) in establishing the clinical 
phenotype of tumors, is an emerging focus of research interest (282).  
 
CONCLUSIONS 
Novel mechanisms of pituitary tumorigenesis have been identified in recent years, both pertaining 
to germline mutations underlying familial tumors and somatic mutations and epigenetic changes 
driving sporadic tumors. Epigenetic modifications have become increasingly important in 
understanding tumorigenesis, as most pituitary tumors are sporadic with no known genetic driver 
mutations (with the exception of a significant proportion of GH-PTs and ACTH-PTs with GNAS and 
USP8 mutations respectively). While novel somatic variants have been identified through whole 
genome and exome sequencing, their role in driving sporadic tumors remains to be established 
through further functional studies. Epigenetic changes at the chromatin (pre-transcription) and RNA 
levels (post-transcription) are especially crucial in determining clinical characteristics such as subtype 
differentiation and local invasion (occasionally through epigenetic mechanisms specific to subtype). 
Indeed, a novel recent multi-omic classification system using somatic mutations, chromosomal 
alterations and the miRNome, methylome, and transcriptome has shown the PIT1 lineage to be the 
main separator driving distinct group classification (15). Such integrated approaches to these genetic 
and epigenetic mechanisms will permit identification of molecular mechanisms of tumorigenesis 
common across different subtypes, as well as specific to tumor subtype, allowing for the 
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Figure 1 Genetic and epigenetic mechanisms of pituitary tumorigenesis 
Genetic mechanisms may be secondary to germline or somatic mutations, while epigenetic 
mechanisms can be mediated at the chromatin level (such as in the case of DNA methylation or 
histone modifications) or via non-coding RNAs. 
 
Figure 2 Germline or mosaic mutations causing pituitary tumors 
Pituitary tumors presenting in isolation (familial isolated pituitary adenoma, FIPA) or part of a tumor 
syndrome. Hyperplasia has been described in Carney complex and McCune-Albright syndrome, in 
20% of XLAG cases and rarely in AIP mutation positive cases.  
Genes marked with red letter types are oncogenes, while the black ones are tumor suppressor 
genes.  
G, germline; S, somatic; M, mosaic; HPGL, hereditary paraganglioma, LCCSCT, large-cell calcifying 
Sertoli cell tumors, pHPT, primary hyperparathyroidism, PPB, pleuropulmonary blastoma, SLCT, 
Sertoli–Leydig cell tumor. 
 
Figure 3 Tumorigenic mechanism in somatotroph cells 
cAMP-associated pathways are key for somatotroph tumorigenesis. GHRH released by the 
hypothalamus interacts with its receptor (GHRH-R) on the somatotroph cell membrane to increase 
activation of adenylyl cyclase through Gαs. Consequent increased cAMP production leads to the 



















which then translocate to the nucleus and phosphorylate CREB (cAMP response element) and other 
targets, eventually leading to increased GH expression and cell proliferation. Mosaic (McCune-
Albright syndrome) or somatic activating mutations in GNAS (coding for Gαs) lead to upregulation of 
the cAMP pathway.  In Carney complex, increased PKA activity, either due to the inhibitory action of 
the regulatory subunit PRKAR1A, or increased catalytic subunit activity (PRKACB) leads to 
tumorigenesis.  
Loss of AIP has been shown to increase cAMP signaling through: i) decreased expression of the G 
inhibitory protein Gαi-2,which mediates the inhibitory effects of somatostatin (SS) on adenylyl 
cyclase;  AIP deficiency is associated with reduced Gαi-2 expression  in human and mouse GH-PTs 
(30); ii) an interaction with phosphodiesterases type 4 (PDE4) (34): expression of type 4 
phosphodiesterase is lower in AIP-mutated GH-PTs compared to sporadic GH-PTs (35) and AIP 
mutations disrupt the interaction of AIP with PDE4A5 in GH3 cells (33); iii) interaction of AIP with 
members of the PKA complex (36,37); iv) AIP deficiency results in reduced ZAC1 levels (38,39); v-vii) 
AIP is associated with mitochondrial proteins TOMM20 and HSPA9 (37,283), the endoplasmatic 
reticulum calcium channel RYR (29) and with secretory vesicles (33), but the exact mechanisms as to 
how these interactions might lead to tumorigenesis are unclear. GPR101 is Gsα-coupled 
constitutively active receptor leading to increased cAMP signaling. The mechanism of GPR101-
related tumorigenesis may occur via a dual mechanism: hypothalamic dysregulation as elevated 
GHRH levels can be measured in some patients, while there may be a direct pituitary action due to 
increased GPR101 expression on pituitary cells. Recently and endogenous ligand has been identified, 
the lipid mediator Resolvin D5 (RsD5), the role of this mediator in the regulation of the GH axis and 
its levels in patients with XLAG is currently unknown. Ectopic expression of GIPR may also lead to an 





















Figure 4 Tumorigenic mechanism in corticotroph cells (141)
USP8 removes ubiquitin tags through its deubiquitinase action from its targets, such as EGFR and 
Smoothened (SMO), preventing them from being degraded in the lysosome and allowing recycling 
back to the cell surface. Increased EGFR and SMO activity leads to increased cAMP signaling and 
POMC levels. Mutated USP8 cannot bind 14-3-3 protein and undergoes cleavage, which increases its 
enzymatic activity, leading to increased deubiquitination of EGFR and SMO with higher expression 
on the cell membrane. Similarly, GLI1 and histone 2a (H2A) are suggested to be target of USP48 
leading to increased activity with USP48 mutations. Loss-of-function of DICER1, TP53, MLH1 and 
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PRL-PTs  Prolactin receptor Increased prolactin-
induced AKT signaling 
and proliferation seen 
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PRL-PTs Forms dimers with 
ligands, increasing their 
DNA binding and 
transcriptional 
function. The identified 
variant p.R317H 
localizes to the ligand-
binding domain of the 
protein and may 
disrupt interactions. 
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PRL-PTs Converts L-tyrosine into 
L-3,4-
dihydroxyphenylalanine 
(L-DOPA), the essential 
and rate-limiting step 
to formation of 
dopamine. Reduced 
dopaminergic activity 
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interaction with an 
extracellular ligand. 
Transfection of GH3 
cells with the 
p.N604T  
IGSF1 variant did not 
significantly affect GH 
production compared 
to wild-type. The 
mutant protein 
showed the same 
pattern of maturation 
and stability as wild-
type when expressed 
in heterologous cells 
and was detected in 










































Table 2: Germline non-synonymous missense variants identified with predictions of pathogenicity using SIFT, PolyPhen and Condel. Variants that could not 
be identified unambiguously have been excluded (PRLR, p.Arg477Trp (78) and p.Glu108Lys (79), and CDH23, p.Arg3138Trp, p.Arg2115His, p.Arg3138Trp, 
p.Asp3296Asn (85)) and have not been included in following Table. The variant associated with TH is a truncating mutation and does not have any 
predictions of pathogenicity using the missense tools. HGVSc, Human Genome Variation Society (HGVS) coding sequence name; HGVSp, HGVS protein 
sequence name; SIFT, Sorting intolerant from tolerant prediction tool 
Gene 
 (symbol) 










CABLES1 18:20716258 ENST00000256925.7:c.532G>A ENSP00000256925.7:p.Glu178Lys 0.0101 deleterious 
low 
confidence 
benign N/A  (77) 






18:20774429 ENST00000256925.7:c.935G>A ENSP00000256925.7:p.Gly312Asp 0.0000601 deleterious  probably 
damaging 
deleterious 





5:35084704 ENST00000382002.5:c.241G>A ENSP00000371432.5:p.Gly81Ser 0.0001328 tolerated benign neutral  (78) 
5:35065862 ENST00000382002.5:c.1198G>C ENSP00000371432.5:p.Glu400Gln 0.000898 tolerated possibly 
damaging 
deleterious 
5:35065513 ENST00000382002.5:c.1547A>T ENSP00000371432.5:p.Asn516Ile 0.0008925 deleterious possibly 
damaging 
deleterious 
5:35084647 ENST00000382002.5:c.298A>G ENSP00000371432.5:p.Ile100Val 0.04221 tolerated benign neutral  (78,79) 
5:35072712 ENST00000382002.5:c.508A>C ENSP00000371432.5:p.Ile170Leu 0.01884 tolerated benign neutral 
5:35065328 ENST00000382002.5:c.1732G>C ENSP00000371432.5:p.Glu578Gln 0.001195 tolerated possibly 
damaging 
deleterious  (79) 
RXRG  1:165378891 ENST00000359842.5:c.950G>A ENSP00000352900.5:p.Arg317His 0.00002495 deleterious probably 
damaging 
Deleterious  (82) 
TH 11:2186469 ENST00000381178.1:c.1420A>T ENSP00000370571.1:p.Lys474Ter not present N/A N/A N/A  (82) 
CDH23 10:73494028 ENST00000224721.6:c.4151G>T ENSP00000224721.6:p.Arg1384Leu not present deleterious probably 
damaging 
deleterious  (85) 
IGSF1 X:130412680 ENST00000370903.3:c.1811A>C ENSP00000359940.3:p.Asn604Thr 0.009383 tolerated probably 
damaging 












































Gene name Hormone 
subtype 
Mechanism of tumorigenesis References  
NR3C1 Nuclear receptor 
subfamily 3 group C 
member 1 
ACTH-PT Glucocorticoid receptor. If mutated, this receptor may become insensitive to feedback from cortisol 
leading to ACTH over-production (154).  
 (125,137,144,155) 
MEN1 Menin 1 Plurihormonal 
(GH/PRL) 
Inactivating mutations underlie multiple endocrine neoplasia type 1, an autosomal dominant 
syndrome with pituitary tumors as part of the phenotype. 
 (105,125) 
KIF5A Kinesin heavy 
chain isoform 5A 
PRL, GT  Modulates cell proliferation. Somatic mutations 
also found in prostate cancer (156) 
 (125) 
GRB10 Growth factor receptor 
bound protein 10 
GH-PT Suppresses signals from activated receptors tyrosine kinases, including insulin-like growth factor type 
1 receptors. Inactivating mutations may allow increased signaling facilitating somatotroph 
tumorigenesis 
 (125) 
BRAF BRAF proto-oncogene, 
serine/threonine kinase 
ACTH-PT Elevated kinase activity with activation of MAPK pathway and transactivation of POMC, which is the 
precursor of ACTH.  
Well-established oncogenic roles in melanoma and multiple carcinomas. 
 (143,144) 
USP48 Ubiquitin specific 
peptidase 48 
ACTH-PT USP48 has been suggested to increase transcriptional activation of POMC through the NF-κB 
pathway, increase response to CRH and possibly involve the hedgehog pathway. 
 (143,144) 
PABPC1 poly (A) binding protein 
cytoplasmic 1 
ACTH-PT Binds the poly (A) tail of mRNA and is involved in regulatory processes such as pre-mRNA splicing and 
regulation of nonsense-mediated decay. 
 (107) 
TP53 Cellular tumor antigen 
p53 


























Insight into tumorigenesis Refer
ences 
GH-PT WGS (40), 
WES (41) 





WES Enhanced promoter activity and increased transcription of POMC through different mechanisms can lead to tumorigenesis.  (144) 
TSH-PT WES Six candidate variants identified, of which two have previously characterized tumorigenic roles: a) Increased expression of SMOX is associated with gastric 
cancer, and b) SYTL3 encodes proteins which interact with RAB27 and deregulation of this pathway is associated with bladder cancer. 
 (160) 
NFPT WES Somatic variants in putative driver genes including platelet-derived growth factor D (PDGFD), N-myc down-regulated gene family member 4 (NDRG4), and 






















Table 5: Varying functions of microRNAs in pituitary tumorigenesis with illustrative examples from publications from the last five years 




demonstrate a tumor 
suppressor action by 
targeting oncogenic gene 
products for degradation 
 
microRNAs regulate the cell 
cycle, facilitating increased 
proliferation when 
deregulated (213) 
miR-23b and miR-130b, targeting HMGA2 and cyclin A2 respectively, are downregulated in GH-PTs, GT-PTs and NFPTs (216). 
HMGA2 is a high mobility group protein, which shows increased expression in pituitary tumors (217,218). HMGA2 
overexpression enhances E2F1 activity and drives cell cycle (219,220) microRNAs targeting HMGA2 and E2F1 are 
downregulated in pituitary tumors (218,221) 
 
miR-410 targeting the cyclin B1 gene is downregulated in GT-PTs (222) 
 
miR-186 targets SKP2, which inhibits expression of p27, a negative regulator of G1 cell cycle progression, increasing 
proliferation. In human pituitary tumors, miR-186 and p27 expression is downregulated, while SKP2 expression is upregulated 
(223). In vitro, SKP2 overexpression decreases p27 expression and increases cell growth (223).  
Multiple microRNAs, when 
downregulated, lead to 
increased expression of PTTG1 
and its partners 
p53 activates transcription of miR-329, miR-300, miR-381, and miR-655 in pituitary tumor cells, which target (224) 
miR-423-5p (targeting PTTG1) shows decreased expression in GH-PTs with increased PTTG1 expression compared to normal 
pituitary (225) 
 
Overexpression of miR-524-5p downregulates expression of PTTG1 binding factor, which interacts with PTTG1 to mediate 
downstream effects (226), and significantly attenuates proliferation, migration, and invasion in folliculostellate cells (227); 
downregulation of this microRNA may mediate increased proliferation in the pituitary through PTTG1 
Other tumor-suppressive 
microRNAs which show 
reduced expression in human 
pituitary tumors or relevant 
cell lines  
miR-205-5p targeting CBX1 in pituitary cell lines (228) 
miR‑1 targeting G6PD in human pituitary tumors (229) 
miR-34a  targeting SOX7 in GH4C1 cells (230) 
miR-378 targeting RNF31 in human pituitary tumors (231) 
Increased expression of 
certain microRNAs can 
drive tumorigenesis by 
targeting gene products 
with tumor suppressor 
roles for degradation 
High levels of miR-107 (232 ) 
and miR-34 (233) target AIP 
mRNA in pituitary tumors 
miR-107 expression is significantly upregulated in GH-secreting and non-functioning pituitary tumors and inhibits in vitro AIP 
expression (232) 
miR-34 is highly expressed in tumors with low AIP protein levels compared to tumors with high levels (233). miR-34 



















Major function Mechanisms of action and/or 
relevant examples 
Supporting evidence 




Distinct profiles identified in 
tumor subtypes with 
differential microRNA 
expression specific to subtype. 
Next generation sequencing and other techniques in GH-PTs, GT-PTs and NFPT subtypes (234,235) 
TSP-1, which has a tumor suppressor role, shows decreased expression in ACTH-PTs with increased miR-449c expression 
inhibiting its expression (236) 
Four groups, miR1 to miR4, are strongly associated with tumor type with PIT1-lineage tumors being distinctly different from 
GT-PTs and ACTH-PTs (15) 
MicroRNAs play a 
prominent role in driving 
tumor invasion 
 
Decreased expression of mi-
RNAs can have an anti-
apoptotic effect, mediating 
invasion: 
Downregulation of miR-132 and miR-15a/16 with upregulation of SOX5 is seen in invasive tumors (237). MiR-15a and miR-16-1 
are also downregulated in pituitary tumors that develop after 12 months of age in mice with heterozygous Men1 knockout 
(238). MiR-16 expression, which induces apoptosis (via Bax) and decreases proliferation, is reduced in pituitary tumors (239) 
 
Invasive pituitary tumors show lower miR-21 expression with increased expression of its target, PITX2, which has an anti-
apoptotic role (240) 
MiR-145-5p expression (targeting TPT1) correlates negatively with NFPT invasiveness. MiR-145-5p brings about apoptosis 
through Bcl-xL downregulation and Bax upregulation (241) 
 
MiR-543 expression is increased in invasive tumors (242) and activates the Wnt/β-catenin pathway by downregulating Smad7. 
Overexpression of miR-543 in HP75 cells increases cell proliferation, migration and invasion and decreases apoptosis (242) 
 
microRNAs driving invasion 
specific to tumor subtype have 
also been identified:  
 
MiR-183, which targets KIAA0101 (a cell cycle activator), is downregulated in aggressive PRL-PTs and demonstrates an inverse 
correlation with Ki-67 indices (243) 
 
MicroRNA 106b~25 cluster shows increased expression in invasive ACTH-PTs and Crooke cell adenomas (244). MiR-106b is 
upregulated in pituitary tumors and can increase migration and invasion of pituitary tumor cells through the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway (245,246) 
 
Differential microRNA profiles have been identified in invasive NFPTs (247) 
 
MiR-26b (targeting PTEN) is upregulated and miR-128 (targeting BMI1) is down-regulated in GH-PTs compared to control and 
is shown to mediate growth and invasiveness of pituitary tumor cells (248). MiR-338-3p expression is increased in invasive GH-
PTs and is mediated through upregulation of PTTG1 (249) 
 
The same microRNAs may even play different roles in different tumor subtypes: miR-410-3p significantly upregulates 
proliferation, invasiveness, cyclin B1 levels and activation of MAPK, PTEN/AKT, and STAT3 signaling pathways in gonadotroph 




















Major function Mechanisms of action and/or 
relevant examples 
Supporting evidence 
Other microRNAs discovered 
recently through comparison 
of invasive and non-invasive 
pituitary tumors (target gene 
in parentheses):  
 
Reduced expression of microRNA in invasive tumors: 
 
microRNA Targeted gene Reference 
miR-145 FSCN1  (251) 
miR-124 PTTG1IP  (251) 
miR-183 EZR  (251) 
miR-148-3p and miR-152 ALCAM  (252) 
miR-200b PKCα  (253) 
miRNA-145 AKT3  (254) 
 
Increased expression of microRNA in invasive tumors: 
miR-26a PLAG1  (255) 






















Essential points: These provide the main takeaway messages from the article. There should be 
between three and seven bulleted points. Each point should consist of a single sentence, although 
there is no character limit imposed on the sentence. 
1. An increasing number of genes with germline mutations are known now to be associated with 
pituitary tumors, some causing syndromic disease while others isolated pituitary adenomas. 
2. Gain-of-function somatic mutations are common in somatotropinomas in the GNAS gene and 
in corticotropinomas in USP8. 
3. Other, less common somatic variants recently identified through next generation sequencing 
need to be confirmed in independent cohorts and elucidated through functional studies in the 
future. 
4. Epigenetic modifications (DNA methylation, histone modification and non-coding RNAs) can 
greatly influence tumorigenesis and tumor characteristics such as subtype differentiation and 
local invasion. 
5. An integrated multi-omics approach to characterize genetic and epigenetic pathways allows 
better understanding the molecular mechanisms that underlie pituitary tumorigenesis within 
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